NexImmune (NASDAQ:NEXI) reported quarterly losses of $(0.69) per share. This is a 27.78 percent decrease over losses of $(0.54) per share from the same period last year.
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside, Supplementation Induces A Potent NAD+ Response And Is Associated With Mild Improvement In Parkinson’s Disease
Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at
